12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga · 05/25 17:31
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga · 05/25 13:07
JMP Securities Reiterates Benitec Biopharma (BNTC) Market Outperform Recommendation
NASDAQ · 05/18 15:22
JMP Securities Reiterates Market Outperform on Benitec Biopharma, Maintains $4 Price Target
Benzinga · 05/18 12:16
JMP Securities Remains a Buy on Benitec Biopharma (BNTC)
TipRanks · 05/18 04:25
Benitec GAAP EPS of -$0.16, revenue of $0.54M
Seeking Alpha · 05/15 14:45
Benitec Biopharma Q3 EPS $(0.16) Up From $(0.40) YoY, Sales $54.00K Up From $48.00K YoY
Benzinga · 05/15 12:22
BRIEF-Benitec Biopharma Releases Third Quarter 2023 Financial Results And Provides Operational Update
Reuters · 05/15 12:07
-- Earnings Flash (BNTC) BENITEC BIOPHARMA Reports Q3 Revenue $54,000
-- Earnings Flash (BNTC) BENITEC BIOPHARMA Reports Q3 Revenue $54,000
MT Newswires · 05/15 08:14
Benitec Biopharm: Current report
Press release · 05/15 08:07
Benitec Biopharm: Quarterly report
Press release · 05/15 08:03
BRIEF-Benitec Biopharma To Regain Compliance With Nasda Bid Price Rule
Reuters · 03/08 21:37
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 02/27 21:31
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 02/23 21:31
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 02/17 21:31
Analysts Offer Insights on Healthcare Companies: Steris (STE), Benitec Biopharma (BNTC) and Bicycle Therapeutics (BCYC)
TipRanks · 02/15 05:30
Benitec GAAP EPS of -$0.20 misses by $0.09
Seeking Alpha · 02/13 13:59
BRIEF-Benitec Biopharma Posts Qtrly Loss Of $0.20 Per Share
Reuters · 02/13 13:32
Webull provides a variety of real-time BNTC stock news. You can receive the latest news about Benitec Biopharm through multiple platforms. This information may help you make smarter investment decisions.
About BNTC
Benitec Biopharma Inc is an Australia-based biotechnology company. The Company is focused on developing a therapeutic technology platform that combines ribonucleic acid (RNA) interference with gene therapy for the goal of silencing disease-causing genes from a single administration. The Company's technology, deoxyribonucleic acid (DNA)-directed RNA interference (ddRNAi), is used to develop product candidates in chronic and life-threatening human disease areas including orphan disease and infectious disease. Its pipeline includes BB-301, and BB-103. The Company's lead product candidate, BB-301, is used for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD). Its BB-103 pipeline product is being developed for the treatment of chronic hepatitis B Virus infection.